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ABSTRACT 
 Mammalian AMP-activated protein kinase (AMPK) is a heterotrimeric 
serine/threonine protein kinase that acts as a sensor of cellular energy status. It interacts 
with a great variety of different substrates leading to short term (i.e. regulation of the 
activity of different enzymes by direct phosphorylation) and long-term effects (i.e. 
regulation of transcriptional activity of different transcription factors). In this work, we 
describe the use of the yeast two-hybrid technology to identify additional proteins that 
interact with the different subunits of AMPK. We have performed three yeast two-
hybrid screenings of a human skeletal muscle cDNA library using three different baits: 
a constitutively active form of AMPK2 (LexA-AMPK2-T172D) co-expressed with 
AMPK1, LexA-AMPK2 and LexA-AMPK3. Our results identify novel interaction 
partners of AMPK in human skeletal muscle. We also further characterize the 
interaction of AMPK with one of these novel interacting proteins, the non-ATPase 
subunit of the proteasome PSMD11. Our results indicate that AMPK is able to interact 
physically with this subunit and modify its phosphorylation status, supporting a possible 
role for AMPK in regulating proteasome function. 
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Abbreviations: AICAR: 5-aminoimidazole-4-carboxamide-1-D-ribofuranoside; 
AMPK: AMP-activated protein kinase; PKA: protein kinase A; SDS-PAGE: sodium 
dodecylsulfate polyacrylamide gel electrophoresis; 2D-E: two-dimensional 
electrophoresis. 
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INTRODUCCION 
Mammalian AMP-activated protein kinase (AMPK) is a serine/threonine protein 
kinase that acts as a sensor of cellular energy status. It is activated in an ultrasensitive 
manner by cellular stresses that deplete ATP, either by inhibiting ATP production 
(hypoxia, glucose deprivation, heat shock, mitochondrial oxidative phosphorylation 
inhibitors, etc.) or by accelerating ATP consumption (muscle contraction, etc.). Once 
activated, it switches on catabolic pathways and switches off many ATP-consuming 
processes (anabolic pathways) (see Hardie and Sakamoto, 2006; Hardie, 2007 for 
reviews). AMPK is an oligomeric complex composed of three different subunits: ,  
and . Phylogenetic analysis of the three subunits indicates that all of them have 
orthologues in the eukaryotic kingdom, from yeast to humans, thus indicating that the 
function of this complex is well conserved throughout evolution (Hardie et al., 1998; 
Hardie et al., 2003). AMPK is the catalytic subunit of the AMPK complex. Two 
isoforms of this subunit have been described, namely AMPK1 and AMPK2. Both 
isoforms are localized in the cytoplasm, although AMPK2 shows also a nuclear 
localization (Salt et al., 1998). The AMPK subunit contains four tandem repeats of a 
structure module called CBS, described initially in cystathionine--synthase (Bateman, 
1997), which is involved in AMP binding (Scott et al., 2004). Three isoforms of the -
subunit, named AMPK1, 2 and 3, have been described. The three isoforms display 
little homology at the N-terminus, but the C-terminus (where the CBS domains are 
located) is conserved. Finally, the AMPK subunit functions as a scaffold to assemble 
the  and  subunits and it also determines the subcellular localization and substrate 
specificity of the complex. Two isoforms of the -subunit (AMPK1 and 2) have been 
described; they differ only at the N-terminus, but interact with the same efficiency with 
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the AMPK and AMPK subunits (Thornton et al., 1998; Gimeno-Alcaniz and Sanz, 
2003). 
AMPK function has been implicated in multiple metabolic pathways. It interacts 
with a great variety of different substrates leading to short term (i.e. regulation of the 
activity of different enzymes by direct phosphorylation) and long-term effects (i.e. 
regulation of transcriptional activity of different transcription factors) (Hardie, 2007). In 
this work we describe the use of the yeast two-hybrid technology to identify novel 
binding partners for the different subunits of the AMPK complex. Of the interacting 
proteins indentified, we have focused our attention on PSMD11, a non-ATPase subunit 
of the lid of the proteasome. 
Proteasomes are one of the major pathways of intracellular protein degradation 
in mammalian cells (Ciechanover, 2005; Hershko, 2005; Rose, 2005; Varshavsky, 
2005). The 26S proteasome complex consists of the 20S catalytic core, where the 
proteins are degraded, plus one or two 19S regulatory complexes. The 19S complex is 
composed of at least 19 different subunits that form a lid and a base-like structure. The 
base includes six ATPases that interact with the 20S proteolytic core; these ATPases 
have chaperone functions and are required for the unfolding of substrates and their 
translocation to the 20S proteolytic chamber. The lid provides the binding sites for poly-
ubiquitinated substrates and a deubiquitinating activity involved in recycling of 
ubiquitin moieties upon substrate degradation (Bajorek and Glickman, 2004; Wolf and 
Hilt, 2004;Meiners et al., 2008). The lid is clustered into two groups of proteins, one 
that is close to the base, which is formed by four subunits, PSMD3 (Rpn3), PSMD6 
(Rpn7), PSMD8 (Rpn12) and SHFM1 (Rpn15) (in parenthesis, the name of the yeast 
orthologue subunits), and another which lays on top of the first cluster, which is 
composed of five subunits, PSMD7 (Rpn8), PSMD11 (Rpn6), PSMD12 (Rpn5), 
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PSMD13 (Rpn9) and PSMD14 (Rpn11) (Fu et al., 2001; Sharon et al., 2006; Murata et 
al., 2009). PSMD11 (Rpn6) is a non-ATPase subunit of the lid of the proteasome. It is a 
protein of 422 amino acids, initially defined as the p44.5 subunit of the lid of the human 
proteasome (Hoffman and Rechsteiner, 1997; Saito et al., 1997), which can complement 
the lethality of a yeast rpn6 mutant (Santamaria et al., 2003). PSMD11 has been 
reported to interact with the C-terminus of NF-kB2/p100, but only when this domain is 
previously phosphorylated and ubiquitinated (Fong et al., 2002). We describe in this 
work that PSMD11 physically interacts with both the catalytic AMPK2 and the 
regulatory AMPK2 subunits of the AMPK complex, and that AMPK can modify the 
phosphorylation status of PSMD11. 
 
MATERIALS AND METHODS 
1.- Microorganisms, culture conditions and genetic methods. 
Escherichia coli DH5 was used as the host strain for plasmid constructions and 
protein production. It was grown in LB (1% peptone, 0.5% yeast extract, 1% NaCl, pH 
7.5) medium supplemented with 50 mg/l ampicillin. Yeast strains used in this work 
were CTY10-5d (MATa ade2 his3 leu2 trp1 gal4 gal80 URA3::lexAop-lacZ; gift from 
R. Sternglanz, State University of New York, Stony Brook, USA) and TAT7 (MATa 
ade2 his3 leu2 trp1 gal4 gal80 LYS2::lexAop-HIS3, URA3::lexAop-lacZ; gift from R. 
Sternglanz, State University of New York, Stony Brook, USA). Yeast transformation 
was carried out using the lithium acetate protocol (Ito et al., 1983). Yeast cultures were 
grown in synthetic complete (SC) medium lacking the corresponding supplements to 
maintain selection for plasmids (Rose et al., 1990). 
 
2.- Plasmids.  
 6
Plasmids used in this study were pBTM116-AMPK2, pBTM116-AMPK2 
(T172D), pBTM116-AMPK2, pACT2-AMPK2, pBTM116-AMPK1, pWS93-
AMPK1 (Solaz-Fuster et al., 2006) and pBTM116-AMPK3A (34-489) (Viana et al., 
2007). The pCMV-HA-AMPK2 and pCMV-HA-AMPK2 plasmids were described in 
(Solaz-Fuster et al., 2006). 
pACT2-PSMD11 was obtained in the two-hybrid screening. It contained the 
complete ORF of PSMD11 fused in frame to the Gal4 activation domain of the pACT2 
plasmid (Legrain et al., 1994). The pCMV-myc-PSMD11 plasmid was constructed by 
digesting plasmid pACT2-PSMD11 with SfiI and XhoI and subcloning the fragment 
into plasmid pCMV-myc (BD-Biosciences) digested with the same enzymes. The 
pGEX6P1-PSMD11 plasmid was constructed by digesting plasmid pACT2-PSMD11 
with SmaI and XhoI and subcloning the fragment into plasmid pGEX6P1 (Amersham 
Biosciences) digested with the same enzymes. The pBTM116-PSMD11 plasmid was 
obtained by digesting plasmid pACT2-PSMD11 with BamHI and SalI and subcloning 
the fragment into plasmid pBTM116 (Vojtek et al., 1997), digested with the same 
enzymes. Oligos PSMD11-5 (5’-
GCATGGATCCCGATGGCGGCGGCGGCGGTGGTG-3’) and PSMD11-2 (5’-
GACCCTCGAGCTATGCCCGGTAATCTGTCAGAGC-3’) were used to amplify by 
PCR a fragment comprising the first 311 amino acids of PSMD11, using pACT2-
PSMD11 as a template. This fragment was sequenced to check that the Taq polymerase 
had not introduced undesired mutations, digested with BamHI and XhoI and subcloned 
into plasmid pBTM116 to obtain the pBTM116-PSMD11 (1-311) plasmid. Similarly, 
oligos PSMD11-3 (5’-GGCGGAATTCGAGCTCCGGGATGACCCAATC-3’) and 
PSMD11-4 (5’-GACCCTCGAGCTATGTCAGTTTCTTGGCTTTG-3’) were used to 
amplify a fragment comprising the C-terminal domain of PSMD11 (312-422). This 
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fragment was digested with EcoRI and XhoI and subcloned into pBTM116 to obtain 
plasmid pBTM116-PSMD11 (312-422). 
The pBTM116-PSMD12 plasmid was obtained amplifying by PCR the PSMD12 
ORF from a brain cDNA library with oligos PSMD12-1 (5’-
GGCTGAATTCATGGCGGACGGCGGCTCGGAG-3’) and PSMD12-2 (5’-
GATCGTCGACTTATTGTAGATTATGTATCATC-3’), digesting the fragment with 
EcoRI and SalI and subcloning it into pBTM116. Similarly, a fragment containing the 
PSMD13 ORF was amplified using oligos PSMD13-3 (5’-
GGGCCATGGAGAATTCTTATGAAGGACGTACCGGGCTTCC-3’) and PSMD13-4 
(5’-GGGCTCGAGCTAGGTGAGGATGTCATGGGCCTG-3’), digested with EcoRI 
and SalI and subcloned into pBTM116 to obtain plasmid pBTM116-PSMD13. Finally, 
a fragment containing the CSN2 ORF was amplified using oligos CSN2-1 (5’-
GGGGGATCCTTATGTCTGACATGGAGGATGATTTCATG-3’) and CSN2-2 (5’-
CCCGTCGACTTAAGCCAGTTTACTGACTACAGCC-3’), digested with BamHI and 
SalI and subcloned into pBTM116 to obtain pBTM116-CSN2. 
 
3.- Yeast two-hybrid screening.  
A two-hybrid screening (Fields and Song, 1989) for proteins that interacted with 
LexA-AMPK2-T172D (plasmid pBTM116-AMPK2 (T172D), see above) was 
carried out in strain TAT7 (see above) co-expressing AMPK1 (plasmid pWS93-
AMPK1; see above). The strain was transformed with a commercial human skeletal 
muscle cDNA library (Clontech). Transformants were selected in SC+2%glucose plates 
lacking tryptophan, leucine, uracil and histidine and were subsequently screened for -
galactosidase activity using a filter lift assay (Yang et al., 1992). Additional two-hybrid 
screenings of the same cDNA library were conducted using LexA-AMPK2 (plasmid 
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pBTM116-AMPK2) or LexA-AMPK3 (34-489) (plasmid pBTM116-AMPK3A (34-
489)) as baits. -galactosidase activity was measured in permeabilized yeast cells and 
expressed in Miller units as described by Ludin and collaborators (Ludin et al., 1998). 
 
4.- Co-immunoprecipitation assay.  
Mammalian HEK293 cells were transfected with the corresponding plasmids by 
the calcium phosphate transfection protocol. Twenty-four hours after transfection, cells 
were harvested with lysis buffer [50 mM TricHCl pH. 7.5, 10 mM NaCl, 2 mM EDTA; 
15% glycerol, 1% nonidet P40, complete protease inhibitor cocktail (Roche) and 1 mM 
PMSF]. Cells were lysed by successive rounds of freezing and thawing. Cell lysates 
were then centrifuged at 1000 x g for 15 min and the soluble fraction was collected for 
immunoprecipitation. Co-immunoprecipitation experiments were carried out with 300 
g of crude protein extracts, in a final volume of 500 l of lysis buffer, and one l of 
anti-HA monoclonal antibodies (Sigma Co) or one l of preimmune serum, as in 
(Solaz-Fuster et al., 2006). Mouse monoclonal anti-myc (BD-Biosciences) antibodies 
were used for immunoblotting. Antibodies were detected by enhanced 
chemiluminescence (ECL) with ECL or ECL plus reagents (Amersham Biosciences). 
 
5.- Expression of recombinant proteins in E.coli.  
E.coli transformants harboring the pGEX6P1-PSMD11 plasmid were grown in 
500 ml of LB/ampicillin. Transformants were grown at 37ºC until the absorbance at 600 
nm reached a value of around 0.3. IPTG was then added to a final concentration of 0.1 
mM, and cultures were maintained overnight at 25 ºC. Cells were harvested and 
resuspended in 20 ml of sonication buffer 50 mM HEPES-NaOH pH 7.0, 150 mM 
NaCl, 10% glycerol, 0.1% Triton X-100, 2 mM DTT, 2 mM PMSF and complete 
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protease inhibitor cocktail (Roche)]. Cells were disrupted by sonication and the fusion 
proteins purified by passing the extracts through columns containing 1 ml bed volume 
of glutathione-sepharose (Amersham Biosciences). GST-fusion proteins were eluted 
from the column with 25 mM glutathione. Samples were stored at -80ºC. 
 
6.- AMPK in vitro phosphorylation assay.  
Two hundred ng of purified GST-fusion proteins were phosphorylated with 50 
mU of AMPK (Upstate), in a final volume of 25 l of a buffer containing 20 mM 
HEPES-NaOH pH 7.0, 1 mM dithiothreitol, 5 mM MgCl2, 200 M AMP and 100 M 
of a mixture of -32P-ATP (3000Ci/mmol) and cold ATP. The reaction was incubated at 
30ºC for 1 hour and stopped by boiling the mixtures in sample buffer. Samples were 
analyzed by SDS-PAGE and autoradiography. 200 ng of GST-fusion proteins were 
analyzed by SDS-PAGE and stained with Coomassie blue. For stoichiometry analysis, 
similar samples were stopped after 5, 10, 20, 40 and 60 min and analyzed by SDS-
PAGE and phosphorimaging for the measurement of 32P incorporation. A GST-ACC 
fusion protein, a generous gift of Dr. Mhairi Towler (University of Dundee), was used 
as a control (Scott et al., 2002). 
 
7.- 2D-electrophoresis.  
Mammalian HEK293 cells were transfected with plasmid pCMV-myc-PSMD11 
and 24 hours after transfection, extracts were prepared in urea lysis buffer (9.7 M urea, 
4% CHAPS, 20 mM DTT). Myc-PSMD11 was analyzed by two-dimensional 
electrophoresis (2D-E) using an IPGphor (Amersham Bioscience, Uppsala, Sweden) 
instrument. For the first dimension (IEF), 50 μg of total protein (in 100 μl of 9.7 M urea, 
4% CHAPS, 20 mM DTT and 0.5 % IPG buffer) were loaded on a 7 cm IPG strip (pH 
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range 4-7) using the following focusing conditions: 500 V for 30 min, 1000 V for 30 
min and 5000 V for 80 min. Electrophoretic separation (second dimension) was 
performed using SDS-PAGE. 
 
8.--phosphatase treatment. 
Mammalian HEK293 cells were transfected with plasmid pCMV-myc-PSMD11 
and 24 hours after transfection, extracts were prepared in -phosphatase buffer (50 mM 
Tric-ClH pH 7.5, 0.1 mM EDTA, 5 mM DTT, 0.01% Brij35) containing 2 mM MnCl2. 
Fifty micrograms of crude extract were treated at 30ºC for 30 min with 50 Units of -
phosphatase (New England Biolabs). Reaction was stopped by adding two volumes of 
urea lysis buffer and analyzed by 2-D electrophoresis as above. 
 
RESULTS 
1.- Identification of novel interaction partners of AMP-activated protein kinase in 
human skeletal muscle. 
1.1.- AMPK2(T172D) plus AMPK1 as bait. 
 Studies on the distribution of the different AMPK subunits in human skeletal 
muscle have demonstrated that the 2-2 subunits account for the majority of the 
AMPK complexes. AMPK3 was found to be associated with 2-2 and accounted for 
20% of the total AMPK activity. The AMPK1 subunit was responsible for the 
remaining activity and AMPK2 was shown to play only a minor role (Wojtaszewski et 
al., 2005). In addition, it has been described that exercise activates 2 but not 1, 
indicating that 2-containing complexes may be involved in the metabolic response to 
exercise (Fujii et al., 2000; Winder, 2001). For these reasons and in order to identify 
novel interaction partners of the AMPK complex in human skeletal muscle, we 
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designed a yeast two-hybrid screening in which we used the constitutively active form 
of human AMPK2 (AMPK2 T172D) as bait. In order to obtain a proper AMPK 
trimeric complex, we overexpressed the human AMPK1 subunit in yeast cells. We 
chose this approach based on our previous results showing that AMPK2 interacts with 
Gal83, the yeast AMPK subunit orthologue, but it does not interact with Snf4, the 
yeast AMPK subunit orthologue; in addition, AMPK1 can also interact with Gal83 
(Gimeno-Alcaniz and Sanz, 2003; Sanz, 2008). In this way, a LexA-AMPK2T172D-
AMPK1-Sc.Gal83 complex could be formed. Yeast cells expressing these constructs 
were used in a two-hybrid screening using a commercial human skeletal muscle cDNA 
library. We screened 106 transformants obtaining 85 initial positive clones. Plasmids 
containing the cDNA sequence of the putative interaction partners were extracted and 
reintroduced into the reporter yeast strain in order to confirm the interaction. 
Additionally, they were introduced into yeast cells expressing AMPK1 and only LexA 
in order to check for self-activating properties of the corresponding cDNAs. Only those 
plasmids that did not have self-activating properties and maintained the interaction with 
the bait were further analyzed. The cDNA of these plasmids was sequenced and the 
sequences characterized by BLAST analysis (Altschul et al., 1997). Thirty three of the 
plasmids were excluded from further analysis because they are likely to represent false 
positives (i.e. the cDNA sequence was out of frame or corresponded to untranslated or 
genomic sequences). The remaining 10 positive clones encoded full-length or almost 
full-length in-frame cDNA inserts (Table I). We quantified the strength of the 
interaction by measuring the -galactosidase activity in these selected transformants 
(Table I). 
 In the screening, we obtained the AMPK2 subunit, which represents a good 
internal control for the procedure (Table I). We also identified a group of cDNAs 
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encoding different cytoskeleton binding proteins, such as Nebulin-related anchoring 
protein (NRAP), which performs an anchoring function linking the terminal actin 
filaments of myofibrils to protein complexes located beneath the sarcolemma (Luo et 
al., 1997); tropomodulin 1 (TMOD), a tropomyosin-regulating protein that binds 
specifically to the N-terminus of tropomyosin and blocks elongation and depolarization 
of tropomyosin-coated actin filaments (Fowler et al., 1993); and myozenin 1 (MYOZ1), 
a muscle-specific calcineurin interacting protein that co-localizes with the Z disc 
proteins alpha-actinin and gamma-filamin (filamin C) and tethers calcineurin to the 
sarcolemma (Takada et al., 2001). Moreover, we identified a group of cDNAs encoding 
for transcriptional regulators, such as pre-B-cell leukemia transcription factor 
interacting protein 1 (PBXIP1), which inhibits the binding of the PBX1-HOX complex 
to DNA and blocks the transcriptional activity of E2A-PBX1 (Abramovich et al., 2000). 
Two other transcriptional regulators indentified in the screening were: the SNW domain 
containing 1, also named SKI-interacting protein (SKIIP), a transcriptional co-activator 
that functions to facilitate vitamin D and other nuclear receptor-mediated transcriptional 
pathways (Baudino et al., 1998), and thyroid receptor interacting protein 6 (TRIP6), a 
transcriptional co-activator of NF-kB-regulated genes (Solaz-Fuster et al., 2006). It is 
worth pointing out that TRIP6 was previously identified by our group in an independent 
two-hybrid screening of a human pancreas cDNA library using LexA-AMPK2 as bait 
(Solaz-Fuster et al., 2006). In addition, we identified a cDNA encoding the ubiquitin-
conjugating enzyme UBE2I, a small ubiquitin-related modifier (SUMO)-conjugating 
enzyme that participates in the sumoylation of different proteins (Watanabe et al., 1996) 
and a cDNA encoding a hypothetical protein (C19orf47) of unknown function 
(Wiemann et al., 2004). 
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1.2.- AMPK2 subunit as bait. 
 Since it is thought that AMPK subunits determine the subcellular localization 
and confer substrate specificity to the AMPK complex (Sanz, 2008), we performed an 
additional yeast two-hybrid screening of human skeletal muscle using LexA-AMPK2 
as bait. We screened 106 transformants and obtained 142 initial positive clones. As 
above, plasmids containing the cDNA sequence of the putative interaction partners were 
extracted and tested for reproducibility of the interaction, self-activating properties and 
their sequences characterized by BLAST analysis. Only 17 positive clones were further 
analyzed, since they encoded full-length or almost full-length in-frame cDNA inserts 
(Table II). We quantified the strength of the interaction by measuring the -
galactosidase activity in these selected transformants (Table II). In the screening, we 
identified the AMPK2 and AMPK1 subunits, which validated the procedure. We also 
identified a group of cDNAs encoding regulators of other protein kinases, such as 
guanine nucleotide-binding protein beta2 like1 (GNB2L1), also named receptor for 
activated protein kinase C (RACK1), which is implicated in regulating the function of 
protein kinase C (PKC) (Ron et al., 1994); the casein kinase 2 beta subunit (CSNK2B), 
the regulatory subunit of casein kinase 2 complex (Rodriguez et al., 2008); and DNA 
damage inducible transcript 4-like (DDIT4L), also named protein regulated in 
development and DNA damage response 2 (REDD2) or hypoxia induced factor 1 
(HIF1)-response protein RTP801-like, which has been recently described as a negative 
regulator of the mammalian target of rapamycin kinase (mTOR) pathway (Corradetti et 
al., 2005). Moreover, we identified a group of cDNAs encoding proteins related to the 
cytoskeleton, such as gamma filamin (FLNC), a member of the family of actin-binding 
proteins involved in reshaping of the cytoskeleton (Thompson et al., 2000) and dystonin 
1 (isoform 2) (DST), a cytoskeleton linker protein capable of anchoring neuronal 
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intermediate filaments to the actin cytoskeleton (Leung et al., 2001). Additionally, we 
identified cDNAs encoding the non-ATPase subunit 11 of the 19S regulatory particle of 
the proteasome (PSMD11), which plays a crucial role in the organization of the lid of 
the proteasome (Hoffman and Rechsteiner, 1997), ferredoxin 1 (FDX1), an iron-sulfur 
protein involved in steroid, vitamin D and bile acid metabolism (Jefcoate et al., 1986) 
and a hypothetical protein (C7orf20) of unknown function (Wiemann et al., 2004). 
 
1.3.- AMPK3 subunit as bait. 
 Although complexes containing AMPK3 account only for 20% of the total 
AMPK activity in human skeletal muscle, this subunit has been proposed to play a 
major role in regulating AICAR (an activator of AMPK) induced AMPK-dependent 
glucose uptake and in restoring glycogen levels after exercise (Barnes et al., 2004). In 
order to identify putative interaction partners of AMPK3, we performed a yeast two-
hybrid screening of human skeletal muscle using this subunit as bait. However, we 
noticed that a fusion between LexA and full-length AMPK3 had self-activating 
properties that prevented this type of analysis. For this reason, we used an N-terminal 
truncated form of AMPK3, lacking the first 33 amino acids [AMPK3-A; (Viana et al., 
2007)] which lacked the self-activating properties. We screened 106 transformants and 
obtained 44 initial positive clones. After the quality controls described above, only 7 
clones were further analyzed and the strength of the interaction was quantified in these 
transformants by measuring the -galactosidase activity (Table III). We identified 
cDNAs encoding alpha-crystallin (CRYAB), a member of the small heat-shock protein 
family (Dubin et al., 1989) and three proteins of unknown function: LIM and cystein 
domains rich 1 (LMCD1), brain protein I3 (BRI3) and neuronal outgrowth associated 
isoform 2 (NGRN) (Wiemann et al., 2004). 
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2.- Analysis of the physical interaction between AMPK and PSMD11, a non-
ATPase subunit of the lid of the proteasome. 
 Among the interaction partners described above, PSMD11 (non-ATPase subunit 
11 of the 26S proteasome), which was isolated from four independent clones, was the 
protein with a defined function that interacted stronger (higher levels of -galactosidase 
activity) with a subunit of the AMPK complex (AMPK2). Since we have recently 
described an involvement of AMPK in regulating the activity of the proteasome 
(activation of AMPK with AICAR or metformin leads to a decrease in proteasome 
function) (Viana et al., 2008), we selected PSMD11 for further analysis. We first 
studied whether PSMD11, in addition to interacting with AMPK2, was able to interact 
with the other subunits of the AMPK complex. As shown in Table IV, yeast two-hybrid 
analyses indicated that PSMD11 was able to interact with AMPK2, although to a 
lesser extent, but not with AMPK1. In order to confirm the physical interaction 
between PSMD11 and AMPK2 and 2 subunits, we performed co-
immunoprecipitation experiments. As shown in Fig. 1, when crude extracts from 
mammalian HEK293 cells expressing HA-AMPK2 and myc-PSMD11 were 
immunoprecipitated with anti-HA antibodies, myc-PSMD11 was recovered in the 
immunoprecipitate. The same result was obtained when crude extracts from HEK293 
cells expressing HA-AMPK2 and myc-PSMD11 were used in the assay (Fig. 1). The 
observed co-immunoprecitation was specific since it did not occur in crude extracts 
from HEK293 cells expressing myc-PSMD11 and an empty plasmid expressing only 
HA, nor did it occur if pre-immune serum was used in the assay instead of the anti-HA 
antibodies (Fig. 1). We also performed co-immunoprecipitation analyses in crude 
extracts from HEK293 cells expressing HA-PSMD11 and myc-AMPK2 or myc-
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AMPK2. Affinity purifying with anti-HA antibodies, we detected myc-AMPK2 and 
myc-AMPK2 in the corresponding immunoprecipitates (not shown). Taken together, 
these results confirmed the physical interaction between PSMD11 and two subunits of 
the AMPK complex: AMPK2 and AMPK2. 
 PSMD11 is a protein of 422 amino acids with a PCI (Proteasome, COP9, eIF3) 
domain at its C-terminus. PCI is a domain present in several subunits of the lid of the 
proteasome (PSMD11, PSMD12, PSMD13, PSMD3 and PSMD6) and in similar 
subunits of the COP9/signalosome and eIF3 (mediator of translation initiation) 
complexes. PCI domains are involved in protein-protein interactions and are essential 
for the correct assembly of the lid of the proteasome (Glickman et al., 1998; Fu et al., 
2001; Glickman and Ciechanover, 2002). In order to map the interaction of the 
AMPK2 subunit within the PSMD11 protein, we constructed two truncated forms of 
PSMD11, one containing the N-terminal domain, but lacking the PCI domain [PSMD11 
(1-311)] and the other comprising the C-terminus of the protein which contains the PCI 
domain [PSMD11 (312-422)]. Yeast two-hybrid analyses indicated that only the 
construct that contained the C-terminus of the protein was able to interact with 
AMPK2, although to a lesser extent (Table V). Since the PCI domain is present in 
other subunits of the lid of the proteasome, we tested whether AMPK2 was able to 
interact with some of these subunits. However, we could not detect any two-hybrid 
interaction between AMPK2 and PSMD12, PSMD13 or CSN2 (a subunit of the 
COP9/signalosome complex closely related to PSMD11) (Table V). These results 
suggest that AMPK2 interacts with the C-terminus of PSMD11 and that the interaction 
does not depend on the presence of a PCI domain itself, but on regions of PSMD11 not 
present in the other PCI-containing proteins tested. 
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 Since PSMD11 interacted with the AMPK complex, we checked whether 
AMPK could phosphorylate this protein in vitro. We purified a GST-PSMD11 fusion 
protein expressed in bacteria for use in in vitro phosphorylation assays. As shown in 
Fig. 2A, AMPK phosphorylated GST-PSMD11 in vitro. We determined the 
stoichiometry of the reaction and compared it with the one obtained for a GST-fusion 
protein containing residues 60-94 of mammalian ACC (Acetyl-CoA Carboxylase), a 
known substrate of AMPK, which is phosphorylated at only one site (Scott et al., 2002). 
Our results indicated that PSMD11 was phosphorylated to a lesser extent than ACC, 
suggesting the presence of only one potential phosphorylation site in PSMD11 (Fig. 
2B). 
We next analyzed whether AMPK could modify the phosphorylation status of 
PSMD11 in vivo. Mammalian HEK293 cells were transfected with a plasmid expressing 
myc-PSMD11 and crude extracts were analyzed by two-dimensional electrophoresis. 
As shown in Fig. 2C, in the 2-D gels, myc-PSMD11 was detected as a single spot. 
However, if cells were treated with AICAR (an activator of AMPK), we observed the 
appearance of a second spot towards the positive pole, with a difference in isoelectric 
point of 0.11 units, which is compatible with the acquisition of one phosphate group 
(Fig. 2C). Similar results were obtained if the cells were co-transfected with a 
combination of plasmids that forms a constitutively active AMPK complex (AMPK2 
T172D, AMPK2, AMPK1; CA-AMPK) (Fig. 2C). We also treated the cells with 
phenformin, a stronger AMPK activator, and observed in this case only one spot that 
moved to the position of the right spot in the analysis described above (Fig. 2C). 
Interestingly, if the crude extracts from phenformin treated cells were dephosphorylated 
with an exogenous phosphatase (-phosphatase), one major spot was detected that 
moved leftwards to the position of the spot observed in the crude extracts from 
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untreated cells (Fig. 2C). These results indicate that AMPK activation can induce the 
phosphorylation of PSMD11 in vivo. 
 We then searched the PSMD11 protein sequence for putative AMPK consensus 
phosphorylation sites, Hyd-(Basic,X)-X-X-Ser/Thr-X-X-X-Hyd, where Hyd can be 
Leu, Met, Ile, Phe or Val, and Basic: Arg, Lys or His (Hardie et al., 2003). We found 
two sites that fulfilled these conditions: FQRAQS14LLST and VERKLS366QMIL. In 
addition, recent global phosphoproteome analyses indicated that Ser14, Ser79 and 
Ser272 of PSMD11 were phosphorylated under certain conditions (Olsen et al., 2006; 
Wang et al., 2007; Dephoure et al., 2008). In order to check if one of these residues was 
phosphorylated by AMPK, we constructed S14A, S79A, S272A and S366A mutants, 
expressed and purified them in bacteria as GST-PSMD11 fusion proteins and subjected 
them to in vitro phosphorylation by AMPK. Unfortunately, all the mutants were 
phosphorylated to the same extent as wild type, so the putative AMPK phosphorylation 
site of PSMD11 remains unknown. 
 
DISCUSSION 
 In this work we have used of the yeast two-hybrid technology to identify novel 
interaction partners for AMPK. The procedure appeared to be more successful when 
using AMPK2 or AMPK2 subunits as bait than when using AMPK3. This result 
probably reflects the functions of the AMPK subunits to regulate the activity of the 
trimeric complex by binding allosteric regulators (AMP, ATP), rather than actively 
participating in conferring substrate specificity. Among the novel interactors, we have 
found that both AMPK2 and AMPK2 interact with proteins related to the regulation 
of the cytoskeleton, suggesting that AMPK might play a role in this process. Moreover, 
we describe that AMPK2 interacts with different components of the transcription 
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machinery, reinforcing the role of AMPK in transcriptional regulation (Leff, 2003; 
McGee and Hargreaves, 2008). An additional concept that arises from our results is that 
AMPK2 interacts with different regulatory components of alternative protein kinases, 
suggesting that AMPK could participate in the regulation of the activity of these 
proteins. However, all these results must be confirmed by alternative methods to verify 
the true role for AMPK in these new pathways. 
 Several approaches have been described so far to identify new AMPK 
interacting proteins, i.e. affinity purification coupled to mass-spectrometry (Al-Hakim 
et al., 2005; Ewing et al., 2007), multidimensional substrate-screen (Tuerk et al., 2007) 
or even two-hybrid screening in bacteria (Fu and Gao, 2009). However, when 
comparing our results with those reported previously, it is clear that depending on the 
technique used, a different set of interacting proteins are identified. In fact, when we 
consulted the major interaction protein databases, i.e. IntAct (Kerrien et al., 2007), 
BioGRID (Breitkreutz et al., 2008) and UniHI (Chaurasia et al., 2009), the majority of 
the entries for the different AMPK subunits were reported by only one method. This is 
probably a reflection of the fact that our knowledge regarding AMPK interacting 
proteins is still far from being complete. 
 In this work, we have further characterized the interaction of AMPK with 
PSMD11, a non-ATPase subunit of the lid of the 26S proteasome. We have confirmed 
this interaction by co-immunoprecipitation and observed that AMPK can modify the 
phosphorylation status of PSMD11, both in vitro and in vivo. We have tried to identify 
the AMPK phosphorylation site(s) by mutating residues in putative AMPK consensus 
sites but all the tested mutants were still phosphorylated by AMPK to the same extent as 
wild type. Additionally, we purified a His-tagged-PSMD11 protein from mammalian 
cells grown under conditions of AMPK activation (phenformin treatment) and subjected 
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it to mass spectrometry analysis, using an approach similar to that which we recently 
reported for another interaction partner of AMPK (R5/PTG) (Vernia et al., 2009). 
However, no phosphorylated peptides were identified. So, we do not have at the 
moment any information about the putative AMPK phosphorylation site in PSMD11. 
As we have recently reported that AMPK downregulates the activity of the 
proteasome (Viana et al., 2008), perhaps it performs this function by affecting the 
phosphorylation status of PSMD11. Additionally, analysis of the data in the UniHI 
protein interaction database (Chaurasia et al., 2009), indicates that both the AMPK and 
AMPK subunits interact with alternative non-ATPase subunits of the lid of the 
proteasome (PSMD6 and PSMD7), which may identify the lid of the proteasome as a 
novel target of AMPK action. In this way, AMPK could participate in the metabolic 
control of proteasome function, as was recently described for another metabolic kinase, 
protein kinase A (PKA) (Zhang et al., 2007a; Zhang et al., 2007b). 
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FIGURE LEGENDS 
Fig. 1: PSMD11 co-immunoprecipitates with AMPK2 and AMPK2. Protein extracts 
(300 g) were prepared from HEK293 cells, transfected with plasmids pCMV-myc-
PSMD11 and pCMV-HA-AMPK2, pCMV-HA-AMPK2 or the empty plasmid 
pCMV-HA. One l of anti-HA or pre-immune serum () was used to 
immunoprecipitate the extracts (IP). Pelleted proteins were analyzed by SDS-PAGE and 
immunodetected with anti-myc (upper panel) and anti-HA (lower panel) monoclonal 
antibodies. Proteins in the input crude extracts (CE; 30 g) were also immunodetected 
with anti-HA and anti-myc antibodies. Molecular weight standards are indicated on the 
left on each panel. 
 
Fig. 2: AMPK modifies the phosphorylation status of PSMD11. A) AMPK 
phosphorylates a GST-PSMD11 fusion protein in vitro. GST and GST-PSMD11 (200 
ng) produced in bacteria were phosphorylated in vitro using 50 mUnits of AMPK 
(Upstate) and [-32P]ATP, in the presence of 200 M AMP. Samples were analyzed by 
SDS-PAGE, stained with Coomasie blue and analyzed by autoradiography. Molecular 
weight standards are indicated on the left. B) Stoichiometry analysis of the in vitro 
phosphorylation of GST-ACC (control) and GST-PSMD11 by AMPK (see Materials 
and Methods). Aliquots of the corresponding reaction mixtures were removed at the 
indicated times for SDS-PAGE and phosphorimaging for the measurement of 32P 
incorporation (molecular weight standards are indicated on the left). Values are 
expressed as mol incorporated phosphate per mol of protein (lower panel). C) AMPK 
phosphorylates PSMD11 in vivo. Cell extracts from HEK293 cells transfected with 
plasmid pCMV-myc-PSMD11 were analyzed by 2D-electrophoresis and western 
blotting using anti-myc monoclonal antibodies (upper panel). Cell extracts from 
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HEK293 cells treated with AICAR (0.5 mM, 2h) or with phenformin (5 mM, 2h) were 
analyzed similarly. Cell extracts from phenformin treated cells were also 
dephosphorylated with -phosphatase as described in Materials and Methods and 
analyzed as above (lower panel). HEK293 cells were also co-transfected with plasmid 
pCMV-myc-PSMD11 and a combination of plasmids that reconstituted a constitutively 
active form of the AMPK complex (pcDNA3-AMPK2 T172D, pcDNA3-AMPK2 
and pcDNA3-AMPK1; CA-AMPK); cell extracts were obtained and analyzed 
similarly. Molecular weight standards are indicated on the right. 
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Table I: Positive clones identified in two-hybrid screening of a human skeletal muscle 
cDNA library using LexA-AMPK2(T172D) as bait (co-expressed with AMPK1). 
Yeast TAT7 cells transformed with plasmids pBTM116-AMPK2-T172D and pWS93-
AMPK1 were co-transformed with a human skeletal muscle cDNA library. Positive 
clones were subjected to BLAST analysis and protein interaction estimated by 
measuring the -galactosidase activity. 
 
 
 
Clon nº 
 
 
Encoded protein (gene name) 
 
NCBI mRNA 
accession nº 
 
Covered protein 
fragment 

-Galactosidase 
(Units) 
 
 
pA-41 
 
Beta2 AMPK subunit (PRKAB2) 
 
NM_005399 
 
Complete ORF 
 
318 
 
pA-3 
 
Nebulin related anchoring protein 
(NRAP) 
 
NM_198060 
 
Last 1477/1730 aa 
 
196 
 
pA-33 
 
Tropomodulin I (TMOD) 
 
BC002660 
 
Complete ORF 
 
183 
 
pA-12 
 
Ubiquitin-conjugating enzyme E2I 
(UBE2I) 
 
NM_003345 
 
Complete ORF 
 
108 
 
pA-46 
 
Pre-b-cell leukemia homeobox 
interacting protein1 (PBXIP1)  
 
NM_020524 
 
Last 196/731 aa 
 
76 
 
pA-38 
 
SNW domain containing 1 (SKIIP) 
 
NM_012245 
 
Complete ORF 
 
65 
 
pA-13 
 
Thyroid receptor interacting 
protein 6 (TRIP6) 
 
BC028985 
 
Last 310/476 aa 
 
59 
 
pA-37, 
pA-40 
 
Myozenin1 (MYOZ1) 
 
NM_021245 
 
Complete ORF 
 
41 
 
pA-17 
 
Hypothetical protein in Chr19 
(C19orf47) 
 
NM_178830 
 
Complete ORF 
 
39 
 
pA-0 
 
none 
 
 
- 
 
- 
 
25 
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Table II: Positive clones identified in two-hybrid screening of a human skeletal muscle 
cDNA library using LexA-AMPK2 as bait. Yeast TAT7 cells transformed with 
plasmid pBTM116-AMPK2 were co-transformed with a human skeletal muscle cDNA 
library. Positive clones were subjected to BLAST analysis and protein interaction 
estimated by measuring the -galactosidase activity. 
 
 
 
Clon nº 
 
 
Encoded protein (gene name) 
 
NCBI mRNA 
accession nº 
 
Covered protein 
fragment 

-Galactosidase 
(Units) 
 
 
pB-3/ pB-124 
 
Alpha2 AMPK subunit (PRKAA2) 
 
NM_006252 
 
Complete ORF 
 
694 
 
pB-8/ pB-14 
 
Hypothetical protein in Chr7 
(C7orf20) 
 
NM_015949 
 
Complete ORF 
 
580 
 
pB-37 
 
Gamma1 AMPK subunit 
(PRKAG1)  
 
NM_002733 
 
Complete ORF 
 
546 
 
pB-5/ pB-55/  
pB-123/ pB-125 
 
Proteasome 26S non-ATPase 
subunit 11 (PSMD11) 
 
NM_002815 
 
Complete ORF 
 
460 
 
pB-48 
 
Ferredoxin 1 (FDX1) 
 
NM_004109 
 
Last 163/184 aa 
 
313 
 
pB-44/ pB-128 
 
Guanine nucleaotide binding 
protein, beta polypeptide 2-like 1 
(GNB2L1) 
 
NM_006098 
 
Last 138/317 aa and 
last 169/317 aa 
 
250/ 43 
 
pB-45/ pB-50 
 
Gamma filamin (FLNC) 
 
NM_001127487 
 
Last 518/2725 aa 
and last 457/2725 aa 
 
176/ 218 
 
pB-141 
 
Dystonin (DST) 
 
NM_001144769 
 
Last 524/3214 aa 
 
73 
 
pB-126 
 
Casein kinase2, beta subunit 
(CSNK2B) 
 
NM_001320 
 
Complete ORF 
 
72 
 
pB-7 
 
DNA damage inducible transcript 
4-like (DDIT4L) 
 
NM_145244 
 
Complete ORF 
 
34 
 
pB-0 
 
none 
 
 
- 
 
- 
 
10 
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Table III: Positive clones identified in two-hybrid screening of a human skeletal 
muscle cDNA library using LexA-AMPK3(34-489) as bait. Yeast TAT7 cells 
transformed with plasmid pBTM116-AMPK3(34-489) were co-transformed with a 
human skeletal muscle cDNA library. Positive clones were subjected to BLAST 
analysis and protein interaction estimated by measuring the -galactosidase activity. 
 
 
 
Clon nº 
 
 
Encoded protein (gene name) 
 
NCBI mRNA 
accession nº 
 
Covered protein 
fragment 

-Galactosidase 
(Units) 
 
 
pG-22, pG-26 
 
Alpha (B) crystallin (CRYAB) 
 
NM_001885 
 
Complete ORF 
 
31 
 
pG-5, pG-6 
 
LIM and cystein domains rich 
1 (LMCD1) 
 
NM_014583 
 
Last 129/365 aa 
 
30 
 
pG-11 
 
Brain protein I3 (BRI3) 
 
NM_015379 
 
Complete ORF 
 
28 
 
pG-3, pG-33 
 
Neugrin (NGRN) 
 
NM_001033088 
 
Last 79/219aa 
 
14 
 
pB-0 
 
none 
 
 
- 
 
- 
 
10 
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Table IV: Two-hybrid interaction of PSMD11 with the different AMPK subunits. 
Yeast TAT7 cells transformed with plasmids pBTM116 (empty), pBTM-AMPK2, 
pBTM-AMPK2 and pBTM-AMPK1 were co-transformed with plasmid pACT2-
PSMD11. Protein interaction was estimated using the yeast two-hybrid system, by 
measuring the -galactosidase activity. Values correspond to means from 4-6 different 
transformants (standard deviation lower than 15% in all the cases). 
 
 
 
Plasmids 
 
-Galactosidase (Units) 
 
 
pBTM-AMPK2 + pACT2-PSMD11 
 
10 
 
pBTM-AMPK2 + pACT2-PSMD11 
 
460 
 
pBTM-AMPK1 + pACT2-PSMD11 
 
<1 
 
pBTM116 + pACT2-PSMD11 
 
 
<1 
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Table V: Two-hybrid interaction of AMPK2 with different domains of PSMD11. 
Yeast CTY10.5d cells transformed with plasmid pACT2-AMPK2 were co-
transformed with plasmids pBTM116-PSMD11 (1-422, full length), pBTM116-
PSMD11 (1-311) or pBTM116-PSMD11 (312-422). Additionally transformants 
containing plasmid pACT2-AMPK2 were also co-transformed with plasmids 
pBTM116-PSMD12, pBTM116-PSMD13 or pBTM116-CSN2 Protein interaction was 
estimated using the yeast two-hybrid system, by measuring the -galactosidase activity. 
Values correspond to means from 4-6 different transformants (standard deviation lower 
than 15% in all the cases). 
 
 
Plasmids 
 
-Galactosidase 
activity (Units) 
 
 
pACT2-AMPK2 + pBTM116-PSMD11 (1-422) 
 
90 
 
pACT2-AMPK2 + pBTM116-PSMD11 (1-311) 
 
<1 
 
pACT2-AMPK2 + pBTM116-PSMD11 (312-422) 
 
30 
 
 
pACT2-AMPK2 + pBTM116-PSMD12 
 
 
<1 
 
pACT2-AMPK2 + pBTM116-PSMD13 
 
<1 
 
pACT2-AMPK2 + pBTM116-CSN2 
 
<1 
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